Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | NSD2 | O96028 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5104057 | 0.85 | KMT2A (0.54) | NPC1RAB9AL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL5065942 | 0.84 | MAPK10 (0.53) | NPC1RAB9AL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL5112027 | 0.81 | MAPK8 (0.58) | L3MBTL1CYP3A4CYP2C19MAPK10MAPK8 | |
| SCHEMBL5106903 | 0.80 | MAPK10 (0.49) | NPC1RAB9AL3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL30216505 | 0.80 | MEN1 (0.53) | L3MBTL1CYP3A4CYP2C19MAPK10KMT2A | |
| SCHEMBL5359973 | 0.77 | CYP3A4 (0.61) | L3MBTL1CYP3A4CYP2C19KMT2ALMNA | |
| SCHEMBL26401375 | 0.76 | HPGD (0.57) | L3MBTL1CYP3A4CYP2C19KMT2ALMNA | |
| SCHEMBL770934 | 0.75 | CYP3A4 (0.87) | L3MBTL1CYP3A4CYP2C19KMT2AEPHX2 | |
| SCHEMBL1285661 | 0.74 | CFD (0.60) | NPC1RAB9AMAPK8KMT2ALMNA | |
| SCHEMBL20976469 | 0.74 | KMT2A (0.57) | L3MBTL1CYP3A4CYP2C19KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| US-7378411-B2 | Substituted thienopyrimidinones as a mitotic kinesin inhibitor | MERCK & CO., INC. (US) | 2008-05-27 | — | — | US | disclosed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1463733-B1 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1551962-A4 | MITOTIC KINESIN BINDING SITE | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060134767-A1 | Mitotic kinesin binding site | MERCK & CO., INC. | 2006-06-22 | — | — | US | disclosed |
| EP-1463733-A4 | MITOTIC KINESIN INHIBITORS | MERCK & CO INC (US) | 2006-01-11 | — | — | EP | disclosed |
| US-20050228003-A1 | Mitotic kinesin inhibitors | MERCK SHARP & DOHME CORP. | 2005-10-13 | — | — | US | disclosed |
| EP-1551962-A2 | MITOTIC KINESIN BINDING SITE | Merck & Co., Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1463733-A2 | MITOTIC KINESIN INHIBITORS | Merck & Co., Inc. (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004004652-A2 | MITOTIC KINESIN BINDING SITE | MERCK & CO., INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2003050064-A2 | MITOTIC KINESIN INHIBITORS | MERCK & CO., INC. (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228003-A1 | Mitotic kinesin inhibitors | KIF5B, KIF18B, KIFC1 | NPC1 1598/4885RAB9A 1375/4885L3MBTL1 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.